insights_auto
Why is DEVA down 2.47%?
Dive Deeperchevron_right
DEVA:IST
Deva Holding AS
TRYÂ 80.95
arrow_downward
-2.47%(-2.05) 1D
Oct 13, 6:10:00 PM GMT+3 · TRY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DEVA...
Open
TRYÂ 82.65
High
TRYÂ 83.25
Low
TRYÂ 80.15
Mkt. cap
16.19B
Avg. vol.
653.35K
Volume
306.70K
52-wk high
TRYÂ 109.30
52-wk low
TRYÂ 57.50
EPS
-TRYÂ 4.21
Shares outstanding
200.02M
No. of employees
3K
Open
TRYÂ 82.65
High
TRYÂ 83.25
Low
TRYÂ 80.15
Mkt. cap
16.19B
Avg. vol.
653.35K
Volume
306.70K
52-wk high
TRYÂ 109.30
52-wk low
TRYÂ 57.50
EPS
-TRYÂ 4.21
Shares outstanding
200.02M
No. of employees
3K
News stories
From web sources and news partners
ChartMill
·
59 minutes ago
Explore the top gainers and losers within the dow jones index in today's session.
The Lufkin Daily News
·
1 hour ago
S&P 500 flat as chipmakers fall and bank earnings roll in
Morningstar
·
58 minutes ago
Wheat Futures Fall; Traders Use Caution — Daily Grain Highlights
شبكة تواصل الإخبارية
·
3 hours ago
Few Stocks are holding the S&P up: Is that a warning? [Video] | FXStreet
Profile
DEVA Holding A.Åž. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS